ToleroMune Ragweed Exposure Chamber Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
It is believe that ragweed is the primary cause of autumn allergies and 87% of patients with ragweed allergy suffer rhinoconjunctivitis. ToleroMune Ragweed is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of ragweed allergy. This study will look at the efficacy, safety and tolerability of two doses of ToleroMune Ragweed in ragweed allergic subjects following challenge with ragweed in an EEC.
Epistemonikos ID: 025c8cdb1e113c6f5260eb227992e3cf303581a3
First added on: May 05, 2024